奥沙利铂或顺铂联合氟尿嘧啶方案治疗食管癌患者的研究  

Study on the Treatment of Esophageal Cancer Patients with Oxaliplatin or Cisplatin Combined with Fluorouracil

作　　者：王宁[1] WANG Ning(Department of Gastrointestinal Oncology,Nanyang Central Hospital,Nanyang Henan 473000,China)

机构地区：[1]南阳市中心医院消化道肿瘤内科,河南南阳473000

出　　处：《临床研究》2024年第12期56-59,共4页Clinical Research

摘　　要：目的分析奥沙利铂或顺铂与氟尿嘧啶联合治疗食管癌的效果。方法选取2022年1月至2023年8月南阳市中心医院收治的62例食管癌患者,遵循随机抽样法分组,B组(n=31)以奥沙利铂、氟尿嘧啶联合治疗,A组(n=31)以顺铂、氟尿嘧啶联合治疗,比较两组不良反应、血清肿瘤标志物水平、临床疗效、生活质量。结果B组疾病控制率、客观缓解率均高于A组,差异均有统计学意义(P<0.05)。治疗前,两组血清肿瘤标志物水平比较,差异无统计学意义(P>0.05),治疗2个周期、治疗结束后,B组各项血清肿瘤标志物水平均低于A组,差异均有统计学意义(P<0.05)。治疗前,两组中文版癌症患者生命质量通用量表(FACT-G)评分比较,差异无统计学意义(P>0.05),治疗2个周期、治疗结束后,B组FACT-G各项评分均高于A组,差异均有统计学意义(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论奥沙利铂、氟尿嘧啶联合治疗食管癌,患者病情得到控制,降低血清肿瘤标志物水平,提高患者生活质量,不会额外增加不良反应,值得临床应用。Objective To analyze the effects of oxaliplatin or cisplatin combined with fluorouracil in the treatment of esophageal cancer.Methods A total of 62 esophageal cancer patients admitted to Nanyang Central Hospital from January 2022 to August 2023 were selected and randomly divided into two groups.Group B(n=31)received treatment with oxaliplatin and fluorouracil,while Group A(n=31)received treatment with cisplatin and fluorouracil.The two groups were compared for adverse reactions,serum tumor marker levels,clinical efficacy,and quality of life.Results The disease control rate and objective response rate in Group B were higher than those in Group A,with statistically significant differences(P<0.05).There were no significant differences in serum tumor marker levels between the two groups before treatment(P>0.05).After two treatment cycles and at the end of treatment,serum tumor marker levels in Group B were significantly lower than those in Group A(P<0.05).Prior to treatment,there were no significant differences in the Chinese version of the Functional Assessment of Cancer Therapy-General(FACT-G)scores between the two groups(P>0.05).After two treatment cycles and at the end of treatment,FACT-G scores in Group B were significantly higher than those in Group A(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of oxaliplatin and fluorouracil for the treatment of esophageal cancer effectively controls the disease,reduces serum tumor marker levels,and improves patients'quality of life without increasing adverse reactions,making it a worthwhile option for clinical application.

关 键 词：食管癌 奥沙利铂 氟尿嘧啶 顺铂 肿瘤标志物 

分 类 号：R735.1[医药卫生—肿瘤]